Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

zafirlukast -

Καναδάς - Αγγλικά - Health Canada

glaxosmithkline inc - benzoyl peroxide; clindamycin (clindamycin phosphate) - gel - 5%; 1% - benzoyl peroxide 5%; clindamycin (clindamycin phosphate) 1% - antibiotics

Καναδάς - Αγγλικά - Health Canada

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 5mg - drotrecogin alfa (activated) 5mg - other miscellaneous therapeutic agents

Καναδάς - Αγγλικά - Health Canada

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 20mg - drotrecogin alfa (activated) 20mg - other miscellaneous therapeutic agents

Καναδάς - Αγγλικά - Health Canada

janssen inc - etravirine - tablet - 100mg - etravirine 100mg - nonnucleoside reverse transcriptase inhibitors

Καναδάς - Αγγλικά - Health Canada

janssen inc - etravirine - tablet - 200mg - etravirine 200mg - nonnucleoside reverse transcriptase inhibitors

Καναδάς - Αγγλικά - Health Canada

glaxosmithkline inc - benzoyl peroxide; clindamycin (clindamycin phosphate) - gel - 3%; 1% - benzoyl peroxide 3%; clindamycin (clindamycin phosphate) 1% - antibiotics

Καναδάς - Αγγλικά - Health Canada

janssen inc - etravirine - tablet - 25mg - etravirine 25mg - nonnucleoside reverse transcriptase inhibitors

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine hydrochloride 25 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)]. a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - baloxavir marboxil -